Use of teplizumab in children and adolescents at risk of type 1 diabetes: perspectives of parents and caregivers from an Italian Pediatric Diabetes Center

• Published in: Acta diabetologica 2024-05, Vol.61 (5), p.635-642
• Main Authors: Bombaci, Bruno, Passanisi, Stefano, Pecoraro, Maria, Sorrenti, Lacrima, Papa, Mattia, Salzano, Giuseppina, Lombardo, Fortunato
• Format: Article
• Language: English
• Subjects: Adolescent; Adolescents; Adult; Antibodies, Monoclonal, Humanized - therapeutic use; Caregivers; Caregivers - psychology; Caregivers - statistics & numerical data; Child; Child, Preschool; Children; Consent; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - drug therapy; Female; Health Education and psycho-social aspects; Health Knowledge, Attitudes, Practice; Humans; Internal Medicine; Italy - epidemiology; Ketoacidosis; Male; Medicine; Medicine & Public Health; Metabolic Diseases; Monoclonal antibodies; Original Article; Parents & parenting; Parents - psychology; Pediatrics; Surveys and Questionnaires; Teenagers
• ISSN: 1432-5233; 0940-5429; 1432-5233
• DOI: 10.1007/s00592-024-02245-w

Aims In view of the imminent introduction of a novel category of disease-modifying treatments for type 1 diabetes (T1D) in European countries, it becomes imperative to understand the existing awareness and viewpoints of parents and caregivers of children and adolescents predisposed to T1D. This study aims to evaluate the perspectives of a cohort of parents and caregivers regarding using teplizumab to delay the onset of T1D in predisposed children and adolescents. Methods This single-center study used a survey-based approach. Parents or caregivers of children and adolescents with T1D having at least one additional child without T1D answered 15 questions assessing their awareness about teplizumab, their potential willingness to provide consent for its administration in case of eligibility, and their expectations regarding potential outcomes. Results Approximately half of the participants (52.6%) expressed readiness to consent to teplizumab administration for their child if the prescription criteria were met in the future. Only 6.3% of parents claimed detailed knowledge about this innovative medication. Notably, parents with prior experience of diabetic ketoacidosis (DKA) demonstrated a higher inclination to consent to teplizumab treatment ( p  = 0.018). Conclusions Our findings underscore the necessity for comprehensive awareness campaigns spreading the current evidence concerning teplizumab in terms of both effectiveness and possible side effects. Additionally, our study reinforces the pivotal role of DKA prevention in successfully integrating disease-modifying treatments into clinical practice.